SSTR2 and non-Hodgkin lymphoma: Using labeled octreotide binding assays, in situ hybridization, immunohistochemistry and RNA-binding assays SSTR2 expression has been shown to be also expressed in a variety of malignant and non-malignant tumors such as pituitary adenoma, meningeoma, neuroblastoma, Non-Hodgkin’s lymphoma, neuroendocrine carcinoid tumors, breast tumors, renal, pancreatic and small cell lung cancers [3].